SCHEMBL3924718

SCHEMBL3924718

COc1cc2ccc(=O)oc2c(OC)c1O

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 9/20 0.78
CA12 O43570 8/20 0.78
CA1 P00915 8/20 0.78
CA7 P43166 8/20 0.78
CA13 Q8N1Q1 8/20 0.78
KDM4E B2RXH2 6/20 0.77
HSD17B10 Q99714 5/20 0.77
MCL1 Q07820 5/20 0.77
ALDH1A1 P00352 4/20 0.77
HPGD P15428 4/20 0.77
MEN1 O00255 3/20 0.77
KMT2A Q03164 3/20 0.77
CASP1 P29466 3/20 0.77
CASP7 P55210 3/20 0.77
CYP2C19 P33261 3/20 0.77
MAPK1 P28482 2/20 0.77
MAPT P10636 2/20 0.77
CYP2C9 P11712 2/20 0.77
TDP1 Q9NUW8 2/20 0.77
SMN1; SMN2 Q16637 2/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30098746 1.00 CA9 (0.78) CA9CA12CA1CA7CA13
SCHEMBL3190311 0.88 CA9 (1.00) CA9CA12CA1CA7CA13
SCHEMBL29396102 0.88 CA9 (1.00) CA9CA12CA1CA7CA13
Fraxetin SCHEMBL43472 0.87 CA9 (1.00) CA9CA12CA1CA7CA13
Fraxetin SCHEMBL30010613 0.87 CA9 (1.00) CA9CA12CA1CA7CA13
Methoxymethane SCHEMBL2253445 0.86 CA9 (0.97) CA9CA12CA1CA7CA13
SCHEMBL30152142 0.86 CA9 (0.66) CA9CA12CA1CA7CA13
SCHEMBL14296936 0.86 CA9 (0.79) CA9CA12CA1CA7CA13
Fraxidin Methyl Ether SCHEMBL2464275 0.85 CA9 (1.00) CA9CA12CA1CA7CA13
SCHEMBL16015213 0.84 CA9 (0.77) CA9CA12CA1CA7CA13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115536932-A Halogen-free flame-retardant insulating cable material and preparation method thereof 国网河南省电力公司镇平县供电公司 2022-12-30 CN claimed
WO-2015081199-A1 COMPOSITIONS AND METHODS FOR TREATING HERPESVIRUS INFECTION THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2015-06-04 WO claimed
US-20070134711-A1 Compositions of eleutherosides capable of modulating protein expresion BONAGURA VINCENT R 2007-06-14 US claimed
US-20030175777-A1 Eleutherosides as adjuncts for vaccines and immune modulation BONAGURA VINCENT R (US) 2003-09-18 US claimed
WO-2003074000-A2 ELEUTHEROSIDES AS ADJUNCTS FOR VACCINES AND IMMUNE MODULATION OMEGA PHARMACEUTICAL, INC. (US) 2003-09-12 WO claimed
JP-60092204-A None JP disclosed
EP-4635472-A1 COSMETIC COMPOSITION COMPRISING AN EXTRACT OF FRAXINUS EXCELSIOR ASH BARK SOLUBILIZED IN JUGLANS REGIA WALNUT SEED OIL AND POLYGLYCERYL-4 OLEATE AND TOCOPHEROL Société De Recherche Cosmétique S.à.r.L. (LU) 2025-10-22 EP disclosed
CN-119757571-A Universal inflammation recovery preparation characteristic spectrum and construction method and application thereof 广西万通制药有限公司 2025-04-04 CN disclosed
CN-119752834-A Oxygen methyl transferase and application thereof in biosynthesis of isofraxidin and fraxidin 中国农业科学院深圳农业基因组研究所(岭南现代农业科学与技术广东省实验室深圳分中心) 2025-04-04 CN disclosed
CN-118641662-B Detection method for simultaneously measuring multiple components in turbidity-resolving, stagnation-resolving and arthralgia-removing formula 福建中医药大学 2025-03-21 CN disclosed
CN-118641662-A Detection method for simultaneously measuring multiple components in turbidity-resolving, stagnation-resolving and arthralgia-removing formula 福建中医药大学 2024-09-13 CN disclosed
CN-118584013-A Method for simultaneously determining contents of various components in turbidity-resolving, stagnation-resolving and arthralgia-removing formula based on UHPLC-QqQ-MS/MS technology 福建中医药大学 2024-09-03 CN disclosed
US-20030175777-A1 Eleutherosides as adjuncts for vaccines and immune modulation BONAGURA VINCENT R (US) 2003-09-18 US disclosed
US-20030175777-A1 Eleutherosides as adjuncts for vaccines and immune modulation BONAGURA VINCENT R (US) 2003-09-18 US disclosed
WO-2003074000-A2 ELEUTHEROSIDES AS ADJUNCTS FOR VACCINES AND IMMUNE MODULATION OMEGA PHARMACEUTICAL, INC. (US) 2003-09-12 WO disclosed
WO-2003074000-A2 ELEUTHEROSIDES AS ADJUNCTS FOR VACCINES AND IMMUNE MODULATION OMEGA PHARMACEUTICAL, INC. (US) 2003-09-12 WO disclosed
US-20020002139-A1 Methods for treating pathologies OMEGA PHARMACEUTICAL, INC. 2002-01-03 US disclosed
WO-1994026282-A1 METHODS FOR TREATING PATHOLOGIES OMEGA PHARMACEUTICALS, INC. (US) 1994-11-24 WO disclosed
JP-S6092204-A COSMETIC LION CORP 1985-05-23 JP disclosed
JP-S0692204-A 0001-01-01 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002139-A1 Methods for treating pathologies TNF, IL5, CCL11 CA9 3859/4885CA12 2513/4885CA1 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.